Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 2
1(50.0%)
2Total
N/A(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03027583Not ApplicableCompleted

The Effect of Probiotic Intervention on Intestinal Permeability

Role: collaborator

NCT01587547Terminated

Amino Acid Profiling of Spent Culture Medium

Role: collaborator

NCT01077466Phase 2Completed

Natalizumab Treatment of Progressive Multiple Sclerosis

Role: collaborator

All 3 trials loaded